Clostridium difficile Infections Disease Pipeline Drugs Assessment: Clinical TraPosted by saikrishna on May 30th, 2018 Clostridium difficile Infections Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018 Clostridium difficile Infections Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018 Overview: Clostridium difficile is a bacterium which infects the bowel and caused diarrhea. This infection is most commonly seen in people who were recently been treated with antibiotics and it can be spread easily to others. Clostridium difficile is also called as C. difficile or C.diff. C.diff infections may cause serious bowel problems. Symptoms of C.diff infections includes watery diarrhea, painful cramps in tummy, dehydration, dry mouth, head ache, loss of weight and appetite etc. C.diff can be diagnosed by enzyme immunoassay, polymerase chain reaction, GDH or EIA. Treatment for Clostridium difficile infection includes antibiotics course. A sample of this report is available upon request @ Segmentation: By Trial Phase, Clostridium difficile Infections pipeline drugs are segmented as:
By Company, Clostridium difficile Infections pipeline drugs are segmented as:
By Drugs, Clostridium difficile Infections pipeline drugs are segmented as:
By Type of Condition Clostridium difficile Infections pipeline drugs are segmented as:
By Route of Administration, Clostridium difficile Infections pipeline drugs are segmented as:
Like it? Share it! More by this author |